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Herpes simplex virus type 2 (HSV-2) is the primary cause of  genital herpes worldwide
and also has a role in facilitating human immunodeficiency virus (HIV) transmission.
The aim of  the study was to determine seroprevalence of  HSV-2 among the subjects
and associated risk factors.
In this cross-sectional study, 207 HIV Positive subjects attending a retroviral Clinic
in Federal Medical Center, Abeokuta, Ogun state were interviewed and had blood
samples taken. The patients were interviewed using a structured questionnaire and
their serum samples were tested for HSV-2 specific immunoglobulin G (IgG)
antibodies using enzyme-linked immunosorbent assay (ELISA) for consented
participation. Prevalence of  HSV-2 antibodies was ascertained and related to
demographics and behavioral variables.
A total of 207 participants were recruited for this study comprising of Sixty-three
(30.4%) male and 144 (69.6%) female HIV positive subjects. Seroprevalence of
HSV-2 was 70.0%. Only 58(28%) had current history of  genital ulcer. Logistic
regression revealed a history of  multiple sexual partners (P value=0.003), oral sex
(P value=0.02) were found to be associated with HSV-2 acquisition in HIV patients.
All other risk factors such as history of  transactional sex, age at sexual debut and
condom use were not significant. The results highlight the potential public health
impact of  HSV-2 particularly in a developing country like Nigeria where HSV-2
testing is not included in our testing and treatment protocol for HIV. This result
should lead to commencement of HSV type-specific serological testing in the HIV
infected population and also high risk groups should be targeted for behavioral
modification messages.
INTRODUCTION
Genital herpes is an infection commonly caused by
human herpes simplex virus type 2 (HSV-2). In Nigeria
and in most regions of the world it has been described
as a silent pandemic with different countries being at
different stages of the epidemic1.
Herpes Simplex Virus (HSV) is an infection that occurs
globally and estimates of its prevalence differ widely
depending largely on the patient population studied.
HSV has largely been described as a very successful
pathogen largely due to its high prevalence, successful
sexual transmissibility rate, association with immune
compromised patients and ability to cause recurrent
disease. Herpes genitalis is the most frequent sexually
transmitted disease (STD) amongst HIV positive
patients, which when symptomatic, is characterized by
periodic recurrences of  painful genital ulcers. 2
Worldwide incidence of  HSV ranges from roughly
65% to 90% and most persons seropositive for HSV
type 2 (HSV-2) have an intermittent reactivation of
the virus on mucosal surfaces3.
Disruption of the epithelial surface and inflammation
of HSV genital ulcers appear to increase the risk of
HIV transmission. Acute or reactivated HSV infection
may stimulate HIV replication, leading to the
progression of  HIV disease. On the reverse side, HIV-
induced immunosuppression results in alterations in
the natural history of HSV leading to more severe
HSV outbreaks and more frequent viral shedding in
persons co-infected with HIV and HSV compared
with those \without HIV infection. The treatment of
HSV can be more challenging in HIV-infected patients.
Higher doses of antiviral drugs may be required, and
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persons infected with HIV have an increased incidence
of  acyclovir resistant HSV-2.
In the United States, one in four sexually active adults
had HSV-2 infection with a 31% increase in HSV-2
prevalence between 1978 and 1990. About 40-60%
attendees in STD clinics have already acquired genital
herpes and 20-35% of  pregnant women are HSV-2
seropositive. Also  Studies have shown that  22% of
adults have  antibodies to HSV-2 and that about
1.6million new cases of   HSV-2 infection occur yearly
in the United States.4,5
Comparably, high HSV-2 rates have been observed in
sub Saharan Africa where HIV prevalence is the highest.
In recent years, a parallel and interesting epidemiological
association has emerged between HSV-2 and HIV
infection. HSV-2 seroprevalence rates are higher in HIV
positive than in HIV negative individuals and are
especially high among HIV positive persons in sub-
Saharan Africa. Multiple mechanisms may explain these
observations; genital ulceration provides a site for HIV
entry on HIV negative persons and the associated
inflammation increases the number of activated cells
that can be targeted by HIV.6 Although symptomatic
and asymptomatic HSV-2 reactivations may promote
HIV shedding in the genital tract and increase HIV
levels in blood7.
Because asymptomatic HSV-2 infections in HIV-
positive persons may be associated with increased
transmission of HIV and may accelerate the course
of HIV disease, screening should generally be offered
to patients with documented HIV and without a history
of  genital herpes. HSV specific education and
counseling should be provided for individuals with
either HSV-2- negative or HSV-2-positive results,
because HSV-2-negative, HIV-infected patients have
a significantly increased risk of  HSV-2 acquisition1.
The HSV-2 pandemic is further reinforced by the HIV
pandemic and vice versa; and it is becoming clear that
the efforts at controlling the spread of HIV may remain
ineffective if  control of  HSV-2 infection, along with
other sexually transmitted infections (STI) is not
integrated.
The diagnosis of HSV presents a challenge for public
health programmes and for clinicians in developing
countries.1 The present study aims to determine the
prevalence of  HSV-2 antibodies and identify probable
risk factors among HIV patients.
METHODOLOGY
This is a descriptive cross-sectional study design, carried
out in the retroviral Clinic of  the Federal Medical Center
Abeokuta, Ogun state, Nigeria. The Federal Medical
Center is a 250 bedded tertiary health institution and
has a retroviral clinic serving about 800 patients. FMC
Abeokuta is a tertiary Healthcare center which provides
healthcare services to the people of  Ogun state and
neighboring Oyo, Ekiti, Osun and Ondo States and
also serves as a referral hospital to secondary and
tertiary hospitals across the country. The study
population consists of the reproductive age group
attending the retroviral clinic Community Medicine and
Primary Care department of  the Federal Medical
Center Abeokuta.
Sample Size




In this study, the proportion in the target population
estimated to have a particular characteristic is 84%1
Where N=the desired sample size (where target
population is greater than 10000)
Z = the standard deviation, usually set at 1.96
P = the proportion of patients estimated to be infected
by HSV-2.
Q = 1.0 - p, i.e. 1.0-0.84 = 0.16
d = degree of accuracy desired usually set at 0.05
Therefore the minimum sample size will be
N = (1.96)2(0.16)(0.84) = 207
(0.05)2




All patients in the reproductive age group attending
the ART clinic.
Exclusion criteria
Non consenting patients or patients’ relatives.
Ethical clearance
Ethical approval was obtained from the Institutional
Review Board of FMC Abeokuta.
Methods of Data Collection
Verbal and written informed consent were sought and
obtained from each of the subjects; thereafter relevant
medical history, socio-demograhic data and other
information obtained from the patients were entered
into a semi-structured close-ended questionnaire.
Laboratory methods
The assay was carried out in the medical microbiology
laboratory of FMC Abeokuta.
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Specimen collection and transport: blood samples were
collected in 5 ml plain vacutainer tubes and allowed to
clot and sera separated by centrifugation at room
temperature. Samples were stored in cryovials at -20C.
The HSV-2 IgG assay procedure utilizes the enzyme-
linked immunosorbent assay (ELISA) kit (IBL
INTERNATIONAL HSV 2 IgG ELISA GMBH
HAMBURG GERMANY). This is a glycoprotein G-
based type-specific ELISA technique and test result is
qualitative. All specimens and kit reagents were brought
to room temperature and gently mixed. Procedures
were performed in accordance with manufacturer’s
instructions. Quality control and test validation was
included into the test protocols.
Principle of the test
This is a glycoprotein G-based enzyme-linked
immunosorbent assay (ELISA) technique. Diluted
serum samples of patients were added to wells
precoated with HSV-2 antigens. Antibodies in the
patient’s sera are bound to the antigens to form immune
complexes. Enzyme-conjugated antihuman globulin
detects any such complexes. A chromogenic substrate
was added to produce a coloured reaction which
intensity depends on the amount of antibody in the
complex. The absorbance of the microwell contents
are read by a reader. The calibrators and controls are
utilized in internal quality control and in qualitiative
interpretation of  the assay.
Materials and Reagents
Materials and reagents include 96 HSV-2 antigen coated
Microwell strips; a 1 x 100ml vial of sample diluents;
6 x 2.0ml vials of calibrators (CAL1, CAL2, CAL3,
CAL 4, CAL 5 and CAL 6);  1 vial of control serum;
a 50ml bottle of washing buffer concentrate; a 16ml
vial of polyclonal anti-IgG-Horseradish peroxidase
conjugate; a 16ml vial of  Tetramethylbezidine/
Hydrogen peroxide (chromogenic substrate); and a
15ml vial of sulphuric acid stop solution. Other
materials include plate sealing foils, micropipettes,
disposable pipette tips, distilled or de-ionized water,
andabsorbent paper.
Procedures for HSV-2 igG assay: details of  the assay
procedure and precautions will be as stated in the
manufacturer’s instructions.
All specimens and kit reagents was brought to room
temperature and gently mixed. The wash buffer was
prepared by diluting the wash concentrate 1 in 10. The
wells are pre-coated with type-specific HSV
glycoprotein G antigens. Dilutions of  the test serum,
controls and calibrator are added into the appropriate
wells. The assay was blanked using the sample diluents.
The well contents are thoroughly mixed and incubated
for 30 minutes at room temperature. HSV antibodies,
if present in the sera, bind to the HSV antigens on the
surface of the well. All liquid is then removed from all
wells and washing was done three times with wash
buffer. Enzyme-antibody conjugate was then added
to each well and incubated for 30 minutes at room
temperature. This was followed by another three-time
wash step. Then a chromogenic substrate was added
to each well and another incubation for 30 minutes at
room temperature was done. The 0.2M sulfuric acid
stop solution was then added. The intensity of the
colour (OD) that develops was measured using an
Elisa reader with a 450nm measurement filter. The
absorbance is proportional to the concentration of
the HSV antibodies. With each set of  tests are 3 sets
of calibrators (CAL1a and CAL1b; CAL2a and
CAL2b; and CAL6) of concentrations 0 U/ml, 5 U/
ml and 100 U/ml.
Quality Control and Interpretation of Results
(qualitative)
The assay is validated if the absorbance(OD) of blank
is less than 0.100; the mean absorbance of negative
control less  than 0.200, the cut off absorbance is
between 0.150 and 1.30 and negative control
absorbance > than cut off.
Interpretation of Results
The sample is positive if the absorbance is greater than
10% over the cut off. And negative when the
absorbance is lower 10% below the cut off.
Data Analysis
Statistical analysis: all data was analyzed using the
Statistical Package for the Social sciences (SPSS) version
15.0. Data was presented using frequency tables, charts,
as appropriate and cross tabulation to study
relationships and association between variables.
Statistical significance was  set at 5%. A logistic
regression was conducted to identify factors
independently associated with HSV-2 infection.
RESULTS
A total of 207 participants took part in the study and
we had 63 males and 144 females. The age range of
the participants was from 14 to 68years, majority of
the patients were in the 26-30 year age group. Majority
of the respondents were from Ogun state 157 (75.8%)
and 50(24.2%) from other states. The tribes of  the
participants ranged from Hausa 5(7.2%), Igbo
27(13%), Yoruba 161 (77.8%). Majority of  the
participants were Christians 124(59.9%). Majority of
the participants were traders 70(33.8%), commercial
sex workers constituted about 6.8% of the patients,
civil servants 14.5% and students 18.8% (Table 1).
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Less than a third of participants had genital ulcers,
vaginal discharge, dyspaerunia, inguinal discomfort,
recurrent ulcers occurred in 42(20.3%) of the patients
(Table 2).
A total of 77(37.2%) participants had a history of
multiple sexual partners, 75(36.2%) had a history of
Alcohol intake, 47(21.3%) had a history of  smoking.
Of the respondents 46(22.2%) practiced anal sex, 67
(32.4%) oral sex and 60(29%) had a history of
transactional sex.  Over half of the participants had a
history of  condom use (Table 3).
Over two thirds of the participants 172 (83.1%) were
currently on antiretroviral. A total of 145(70%) of the
patients were HSV-2 seropositive and almost over 85%






































Civil Servant 30 14.5
Others 14 6.8
Retroviral status of partners
Positive 61 29.5
Negative 146 70.5























Table 2: Common Clinical signs and symptoms
among the participants





























History of transactional sex
Yes 59 28.5
No 148 71.5
Table 3: Risk factors for HSV-2 among the participants













Positive Negative Total P-
Value
Age
10-15 2(40%) 3(60%) 5(100%)
16-20 13(61.9%) 8(38.1%) 21(100%)
21-25 15(71.4%) 7(28.6%) 22(100%)
26-30 25(73.5%) 9(26.5%) 34(100%)
31-35 21(87.5%) 3(12.5%) 24((100%) 0.428
36-40 17(60.7%) 11(39.3%) 28(100%)
41-45 20(71.4%) 8(28.6%) 28(100%)
46-50 19(65.5%) 10(34.5%) 29(100%)
>50 12(75.0%) 4(25.0%) 16(100%)
Sex
Male 41(65.1%) 22(34.9%) 63(100%) 0.302
Female 104(72.2%) 40(27.8%) 144(100%)
Table 5: Age and sex in relation to HSV-2 seropositivityTable 4: Seropositivity and CD4 count of  the
participants.
Yes No Total P-Value
Age at Sexual Debut
<10 10(76.9%) 3(24.1%) 13 (100%)
11-15 18(58.1%) 15(41.9%) 31(100%)
16-20 51(71.8%) 20(28.2%) 71(100%) 0.708
>20 65(64.3%) 27(29.3%) 92(100%)
Papular eruptions
Yes 57(72.2%) 22(27.8%) 79(100%) 0.579
No 87(68.5%) 41(31.2%) 128(100%)
Genital ulcer
Yes 41(71.9%) 16(28.1%) 57(100% 0.695
No 104(69.1%) 46(30.1%) 150((100%)
Dysuria
Yes 40(67.8%) 20(32.2%) 60(100%)
No 104(70.7%) 43(29.3%) 147(100%)
Dyspaerunia
Yes 41(71.9%) 16(28.1%) 57(100%) 0.585
No 104(68.7%) 46(31.3%) 150(100%)
Recurrent ulcers
Yes 28(68.3%) 13(31.7%) 41(100%)
No 116(70.3%) 49(29.7%) 165(100%) 0.802
Multiple sexual partners
Positive 58(76.3%) 18(23.7%) 76(100%)
Negative 87(66.2%) 44(33.8%) 131 (100%) 0.125
Condom use
Positive 76(69.7%) 33(30.3%) 109(100%) 0.953
Negative 69(70.1%) 29(29.9%) 98(100%)
Any drug abuse
Positive 34(64.2%) 19(35.8%) 53(100%)
Negative 111(71.9%) 43(28.1%) 154(100%) 0.289
Anal sex
Positive 32(71.1%) 13(28.9%) 45(100%) 0.785
Negative 112(69.4%) 50(30.6%) 162(100%)
Oral sex
Positive 42(63.6%) 24(36.4%) 66(100%)
Negative 102(72.9) 39(27.1%) 141(100%) 0.178
History of transactional sex
Positive 43(72.9%) 16(27.1%) 59(100%)
Negative 102(68.5%) 46(31.5%) 148(100%) 0.665
Currently on antiretrovirals
Yes 120(70.2%) 52(29.8%) 172(100%)
No 24(68.6%) 11(31.4%) 35(100%)
Table 6: Clinical presentation and HSV-2
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In relating age and sex, it observed the following that
the most affected group is the 31-35 21(87.5%), while
the least affected group was the 10-15 age group, there
was no significant association between age and HSV-
2 seropositivity (p value=0.428).
Forty one (65.1%) of  the males were HSV-2
seropositive compared with One hundred and four
(72.2%) observed among the females. Although more
females were seropositive to HSV-2, There is no
significant difference in the prevalence of  HSV-2
infection between both sexes (x2 =0.545, p-value=
0.302) (Table 5). Age at sexual debut was not a
significant factor to HSV-2 Acquisition.
Fifty eight 58(28.2%) of the respondents who were
seropositive had a history of  multiple sexual partners.
History of multiple sexual partners was not a significant
factor to HSV-2 acquisition. (X2=2.354, p value=0.125)
(Table 6).
Thirty four (16.5%) of the respondent had history of
drug use while 110(53.4%) did not. History of drug
use was not a significant factor to HSV-2 acquisition.
(X2 =1.122, P value 0.289). Thirty two (15.5%) of the
respondents had anal sex against 111(53.9%) who do
not have anal sex. Anal sex was not a significant factor
in HSV acquisition (X2=0.483 p value=0.785) (Table
6).
Forty two (29.2%) of  the respondents had a history
of oral sex while 102 did not have a history oral sex.
Oral sex did not contribute significantly to HSV
acquisition. (X2=1.813, p value=0.178). Forty three
(29.9%) of respondents had a history of transactional
sex while 101(70.1%) had no history of transactional
sex (X2=0.817, p value=0.665) (Table 6).
One hundred and twenty (83.3%) of the respondents
were on antiretrovirals when compared to 24 (16.4%)
who were not ARV there was no significance in HSV
acquisition. (X2 =0.036, p value=0.850) (Table 6).
DISCUSSION
Serological testing showed that the prevalence of HSV-
2 was 70.0%.This result is consistent with HSV-2
prevalence reported in a multi-centre study in two sub-
Saharan Africa cities: 90.0% in Cotonou Benin Republic;
84.1% in Yaoundé1. Majority of  the participants affected
belonged to 31-35yr age group showing affectation
was in the young adult population and economically
productive group this is in keeping with studies where
the most affected group was the 30-32 age group.8
Globally, seroprevalence of  HSV-2 is higher in the
female sex compared to the males in this study the
prevalence in females was 72.2% compared to 65.1%
in males, this contrasts with studies from a study9 where
the prevalence was higher in the males.
In this study traders and commercial sex workers had
a high seropositivity rate this is in keeping with reports
from Jos.10 The two groups have opposite motivations
while the traders have the money to induce sexual
activity, the CSW trades in sex for gratification thus
exposing both groups to HSV-2 infection.
Age at sexual debut did not significantly affect HSV-2
infection, seropositivity was highest in the > 20 and
lowest in the <10 group, this is in keeping with studies
by Obasi et al but was in contrast to a study carried
out in India9 which showed that younger age at sexual
debut increases risk of  HSV-2 acquisition as these group
are impressionable, immature and susceptible to the
guile of older men.
Seropositivity was highest in the group with history
of multiple sexual partners when compared to those
who had no history of multiple sexual partners, this is
in keeping with studies9 which showed that >3 lifetime
sexual partners may predispose to HSV-2 infection
the reason for this is that the more the number of
sexual contacts the higher the chances of contracting
the infection. Amongst those who used condoms,
seropositvity was higher in the group that did not use
condoms compared to 69% who did use condoms
this is in keeping with studies9 which shows that despite
improper condom some measure of protection is
afforded by condom usage.
Seropositivity was higher in people who practiced anal
sex than those who did not. Anal sex is a risk for both
HIV and HSV 2 infection. 72.9% of those with history
of transactional sex were seropositive compared to
68.5% who were seropositive with no history of
transactional sex. There is a higher rate of  HSV-2
seropositivity in patients who had a history of
transactional sex this is supported by studies11 where
there was an increase in HSV-2 in patients who had
transactional sex.
Over 41(70%) of all participants who presented with
genital ulcers tested positive for HSV-2 compared to
103(69.1%) who had no genital ulcer but tested positive
to HSV-2. Seropositivity was highest in the population
who had no history of genital ulcer this proves that
absence of  an ulcer does not indicate absence of  HSV-
2 this is in keeping with studies that the abscence of
genital ulcers does not preclude HSV-2 seropositivity
as the prescence of HIV enhances the shedding of
HSV-2 even in asymptomatic individuals.9
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On logistic regression of the variables to rule out
confounding risk factors only a history of multiple
sexual partners and history of oral sex were risk factors
for HSV-2 acquisition in HIV patients. This is in keeping
with various studies which show that having multiple
sexual partners lead to HSV-2 acquisition.
CONCLUSION
Sexually transmitted infections in particular HSV-2
infections are common in HIV-infected patients
attending care in ART clinics in Nigeria. The
implication of the findings is that patients should be
regularly screened and subsequently treated for Herpes
where found positive as several epidemiological and
laboratory studies have suggested a biological
plausibility of  HSV-2 infection facilitating the
acquisition and transmission of  HIV-1. Recurrent
episodes of  HSV-2 may increase the susceptibility to
HIV-1 infection in HSV-infected individuals by
activating HIV-1 target cells in the genital tract. In
resource-limited countries where both infections are
prevalent efforts at symptomatic and diagnostic
screening and treatment of  HSV-2 could be part of
the preventive measures for HIV-1. Furthermore, this
study identified specific high risk behaviors – early onset
of sexual debut, multiple sexual partners and oral sex
– that could be used in crafting messages for HIV-1
prevention programs.
The strength of the study was that prevalence of HSV
2 in HIV patient was high even in asymptomatic
patients, which brings about the need to have routine
surveillance and treatment of  HSV 2 in retroviral
patients.
LIMITATION
There was no limitation.
RECOMMENDATIONS.
The Ministry of Health should ensure the integration
of  screening and treatment of  HSV-2 in the current
ARV protocols in the country and also initiate a mass
campaign to discourage having multiple sexual partners
and been involved in risky sexual behaviours.
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